Home Infusion Therapy Global Market Opportunities and Strategies to 2035

This report describes and explains the home infusion therapy market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global home infusion therapy market reached a value of nearly $35.61 billion in 2025, having grown at a compound annual growth rate (CAGR) of 9.4% since 2020. The market is expected to grow from $35.61 billion in 2025 to $54.4 billion in 2030 at a rate of 8.8%. The market is then expected to grow at a CAGR of 8.1% from 2030 and reach $80.4 billion in 2035.

Growth in the historic period resulted from rising prevalence of autoimmune disorders, growing number of surgical procedures and post-operative care needs, increasing prevalence of chronic diseases and high prevalence of infectious diseases. Factors that negatively affected growth in the historic period were strict regulatory and compliance requirements and safety concerns regarding adverse drug reactions.

Going forward, growing aging population, expansion of home healthcare services, growing incidence of hospital-acquired infections (HAIs) and rising demand for convenient long-term therapy administration will drive the growth. Factors that could hinder the growth of the home infusion therapy market in the future include shortage of skilled healthcare professionals, limited reimbursement coverage and impact of trade war and tariffs.

Market trends for the home infusion therapy market include emphasis on expanding in-home infusion care services, expanding home infusion nursing services and connected and digitally integrated infusion platforms.

The home infusion therapy market is segmented by product into infusion pumps, intravenous sets, IV cannulas and needleless connectors. The infusion pumps market was the largest segment of the home infusion therapy market segmented by product, accounting for 49.5% or $17.64 billion of the total in 2025. Going forward, the needleless connectors segment is expected to be the fastest-growing segment in the home infusion therapy market segmented by product, at a CAGR of 10% during 2025-2030.

The home infusion therapy market is segmented by administration into intravenous, subcutaneous, epidural and intramuscular. The intravenous market was the largest segment of the home infusion therapy market segmented by administration, accounting for 70.1% or $24.96 billion of the total in 2025. Going forward, the subcutaneous segment is expected to be the fastest-growing segment in the home infusion therapy market segmented by administration, at a CAGR of 10% during 2025-2030.

The home infusion therapy market is segmented by application into total parenteral nutrition, anti-infective therapy, hydration therapy, chemotherapy, IVIg or specialty pharmaceuticals and other applications. The anti-infective therapy market was the largest segment of the home infusion therapy market segmented by application, accounting for 28% or $9.97 billion of the total in 2025. Going forward, the IVIg or specialty pharmaceuticals segment is expected to be the fastest-growing segment in the home infusion therapy market segmented by application, at a CAGR of 11.4% during 2025-2030.

The home infusion therapy market is segmented by end user into patients, nurse and other end users. The patients market was the largest segment of the home infusion therapy market segmented by end user, accounting for 56.8% or $20.24 billion of the total in 2025. Going forward, the patients segment is expected to be the fastest-growing segment in the home infusion therapy market segmented by end user, at a CAGR of 9.5% during 2025-2030.

North America was the largest region in the home infusion therapy market, accounting for 38.5% or $13.69 billion of the total in 2025. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the home infusion therapy market will be Asia Pacific and North America where growth will be at CAGRs of 10.3% and 8.8% respectively. These will be followed by Eastern Europe and Middle East where the markets are expected to grow at CAGRs of 8.5% and 8% respectively.

The global home infusion therapy market is fairly fragmented, with a large number of small players operating in the market. The top 10 competitors in the market made up 17.7% of the total market in 2024. Option Care Health Inc. was the largest competitor with a 4.50% share of the market, followed by CVS Health Corp. with 4.24%, Baxter International Inc. with 2.51%, B. Braun Melsungen AG with 1.95%, Fresenius SE with 1.67%, CareCentrix Inc. with 0.91%, ICU Medical Inc. with 0.90%, KabaFusion Holdings LLC with 0.62%, CarepathRx LLC with 0.23% and Becton, Dickinson & Company with 0.20%.

The top opportunities in the home infusion therapy market segmented by product will arise in the infusion pumps segment, which will gain $9.98 billion of global annual sales by 2030. The top opportunities in the home infusion therapy market segmented by administration will arise in the intravenous segment, which will gain $13.07 billion of global annual sales by 2030. The top opportunities in the home infusion therapy market segmented by application will arise in the anti-infective therapy segment, which will gain $6.06 billion of global annual sales by 2030. The top opportunities in the home infusion therapy market segmented by end user will arise in the patients segment, which will gain $11.59 billion of global annual sales by 2030. The home infusion therapy market size will gain the most in the USA at $6.3 billion.

Player-adopted strategies in the home infusion therapy market include focus on expanding its operational capabilities through strategic partnerships and expanding its operational capabilities through new launches.

Market-trend-based strategies for the home infusion therapy market include focus on expanding in-home infusion care services, expanding home infusion nursing services and connected and digitally integrated infusion platforms to improve remote patient monitoring, treatment efficiency, and home-based care delivery.

To take advantage of the opportunities, the analyst recommends the home infusion therapy companies to focus on expanding home-based oncology infusion services, focus on integrated home infusion care and chronic disease management, focus on connected remote monitoring and digital infusion platforms, focus on expanding needleless connector solutions for home infusion care, focus on expanding subcutaneous home infusion therapies, expand in emerging markets, continue to focus on developed markets, focus on value-based and reimbursement-aligned pricing strategies, focus on clinical education and outcome-based awareness programs, focus on expanding ivig and specialty pharmaceutical home infusion services, focus on strengthening patient-centered home infusion care models.

This product will be delivered within 3-5 business days.